Corvus Pharmaceuticals Provides PTCL Futility Analysis Timeline and Cash Runway Guidance
Corvus Pharmaceuticals (CRVS) has provided updated clinical and financial guidance, projecting that the futility analysis for its PTCL program is expected in the first quarter of 2027. The company also indicated that its current cash runway is projected to extend into the second quarter of 2028. Financially, the company reported a significant increase in research and development spending. For the third quarter of 2026, R&D expenses reached $17.8 million, more than doubling the $8.5 million reported during the same period in 2025. This increased expenditure reflects the ongoing clinical development efforts driving the company's pipeline.
Tickers: $CRVS
Topics: net loss quarterly earnings R&D expenses